AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19014835 — intervention group
Group type: COMPARATOR
Intervention: Atazanavir monotherapy
Number of subjects: 48
Study 19014835 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevirimat + atazanavir
Number of subjects: 48
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 100 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 200 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous midazolam (1 mg) after 400 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 100 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 200 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alfentanil (15 microg/kg) after 400 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam (3 mg) after 100 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alfentanil (40 microg/kg) after 100 mg fluconazole
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil miosis
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point concentrations of midazolam
Number of subjects: 12
Study 16172184 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-point concentrations of alfentanil
Number of subjects: 12
Study 12509615 — intervention group
Group type: EXPERIMENTAL
Intervention: DIL with additional verbal backup
Number of subjects: 100
Study 12509615 — intervention group
Group type: COMPARATOR
Intervention: DIL alone (control group)
Number of subjects: 100
Study 10434153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 237
Study 10434153 — intervention group
Group type: COMPARATOR
Intervention: Tianeptine 37.5 mg/day
Number of subjects: 237
Study 8909821 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitral valve replacement with chordal preservation
Number of subjects: 12
Study 8909821 — intervention group
Group type: COMPARATOR
Intervention: Mitral valve replacement with chordal excision
Number of subjects: 12
Study 1931347 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 17
Study 1931347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6182817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alloferin (alcuronium) in burned patients, initial dose 23.75 mg (0.35 mg/kg)
Number of subjects: 12
Study 6182817 — intervention group
Group type: COMPARATOR
Intervention: Alloferin (alcuronium) in control group, initial dose 15 mg (0.21 mg/kg)
Number of subjects: 12
Study 31492121 — intervention group
Group type: EXPERIMENTAL
Intervention: Uitblinkers intervention (three sessions between an oral healthcare professional and parent)
Number of subjects: 40
Study 31492121 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 40
Study 29267221 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g whey protein (120 kcal)
Number of subjects: 32
Study 29267221 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 g whey protein (280 kcal)
Number of subjects: 32
Study 29267221 — intervention group
Group type: COMPARATOR
Intervention: Flavored-water control drink (2 kcal)
Number of subjects: 32
Study 29267221 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein ingestion
Number of subjects: 32
Study 24304658 — intervention group
Group type: EXPERIMENTAL
Intervention: OPUS treatment
Number of subjects: 547
Study 24304658 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 547
Study 24359313 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-804 1200 mg
Number of subjects: 0
Study 24359313 — intervention group
Group type: EXPERIMENTAL
Intervention: SPN-804 2400 mg
Number of subjects: 0
Study 24359313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21966947 — intervention group
Group type: COMPARATOR
Intervention: K301a + b (Study I)
Number of subjects: 299
Study 21966947 — intervention group
Group type: COMPARATOR
Intervention: K301a (Study II)
Number of subjects: 299
Study 21966947 — intervention group
Group type: COMPARATOR
Intervention: K301 (both studies)
Number of subjects: 299
Study 19318138 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 258
Study 19318138 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (plasma levels > or =1800 ng/ml)
Number of subjects: 258
Study 19318138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 17465476 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 181
Study 17465476 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 181
Study 15162890 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tobramycin every 24 hours (10 mg/kg/dose for patients aged 6 months to < 9 years, 8 mg/kg/dose for 9 to < 12 years, 6 mg/kg/dose for ≥ 12 years)
Number of subjects: 60
Study 15162890 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin every 8 hours (2.5 mg/kg/dose)
Number of subjects: 60
Study 15162890 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tobramycin every 24 hours
Number of subjects: 60
Study 16085504 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch
Number of subjects: 0
Study 16085504 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 0
Study 10575068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbothane insole
Number of subjects: 11
Study 10575068 — intervention group
Group type: EXPERIMENTAL
Intervention: Cambion insole
Number of subjects: 11
Study 10575068 — intervention group
Group type: COMPARATOR
Intervention: Control (no insoles)
Number of subjects: 11
Study 8762219 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 50 mg slow release form (n = 57)
Number of subjects: 111
Study 8762219 — intervention group
Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily (n = 54)
Number of subjects: 111
Study 1756043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g single preoperative dose)
Number of subjects: 127
Study 1756043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 6124442 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (5 mg i.v.)
Number of subjects: 14
Study 6124442 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (20 mg i.v.)
Number of subjects: 14
Study 6124442 — intervention group
Group type: COMPARATOR
Intervention: Practolol (10 mg i.v.)
Number of subjects: 14
Study 6124442 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg x 2, oral)
Number of subjects: 14
Study 6124442 — intervention group
Group type: COMPARATOR
Intervention: Placebo (oral)
Number of subjects: 14
Study 30807456 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal hemorrhoidal dearterialization with mucopexy
Number of subjects: 80
Study 30807456 — intervention group
Group type: COMPARATOR
Intervention: Vessel-sealing device hemorrhoidectomy
Number of subjects: 80
Study 29561483 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed conventional/piezosurgery preparation
Number of subjects: 26
Study 29561483 — intervention group
Group type: COMPARATOR
Intervention: Conventional preparation with drills
Number of subjects: 26
Study 29561483 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 27001425 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40
Study 27001425 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 40
Study 25011352 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet (maximum dose 32 DU in adults, 12 DU in children), administered once daily for 28 days
Number of subjects: 143
Study 25011352 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered once daily for 28 days
Number of subjects: 143
Study 25011352 — intervention group
Group type: EXPERIMENTAL
Intervention: HDM SLIT-tablet (maximum dose 12 DU in children), administered once daily for 28 days
Number of subjects: 143
Study 22739396 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg/day
Number of subjects: 76
Study 22739396 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 76
Study 20584227 — intervention group
Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg administered within 1 h of pain onset and when pain was mild (early + mild intervention group)
Number of subjects: 501
Study 16950591 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving training combined with education on DASH diet
Number of subjects: 78
Study 16950591 — intervention group
Group type: COMPARATOR
Intervention: Education on DASH diet alone
Number of subjects: 78
Study 15616079 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg IV morphine
Number of subjects: 66
Study 15616079 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 0.5% bupivacaine infiltrated subcutaneously
Number of subjects: 66
Study 15616079 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled 50% nitrous oxide in oxygen (Entonox) via a demand valve
Number of subjects: 66
Study 11851182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracutaneous injections of botulinum toxin (Botox) 2.5 U/0.1 ml, injected at 0.5 U/cm2 with 1 cm distance between injection points.
Number of subjects: 4
Study 10468682 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 60)
Number of subjects: 120
Study 10468682 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 60)
Number of subjects: 120
Study 10468682 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 80 mg b.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (FCM group; n = 52)
Number of subjects: 120
Study 10468682 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg o.d., clarithromycin 250 mg b.d. and metronidazole 500 mg b.d. (OCM group; n = 57)
Number of subjects: 120
Study 8589025 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 8 mg/m2 on days 1-2, 8-9, 15-16, 22-23 and 5-fluorouracil 300 mg/m2 on days 3-7, 10-14, 17-21, 24-28 (35-day courses)
Number of subjects: 44
Study 31259883 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotype-guided warfarin dosing
Number of subjects: 2264
Study 31259883 — intervention group
Group type: COMPARATOR
Intervention: Traditional clinically guided warfarin dosing (Control)
Number of subjects: 2264
Study 29164409 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week program of behavioral activation emphasizing safe-sun exposure (N=10)
Number of subjects: 20
Study 29164409 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (N=10)
Number of subjects: 20
Study 26754176 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone administered at home
Number of subjects: 188
Study 26754176 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin administered in hospital
Number of subjects: 188
Study 24961194 — intervention group
Group type: EXPERIMENTAL
Intervention: SCS-ACTIVE (delivered at 90% paraesthesia threshold)
Number of subjects: 9
Study 24961194 — intervention group
Group type: COMPARATOR
Intervention: SCS-INACTIVE
Number of subjects: 9
Study 22855599 — intervention group
Group type: EXPERIMENTAL
Intervention: CD25(POS)
Number of subjects: 657
Study 19470925 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (225 mg/m²) plus Carboplatin (AUC 6)
Number of subjects: 0
Study 19470925 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic variants analysis
Number of subjects: 0
Study 19470925 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4*1B
Number of subjects: 0
Study 19470925 — intervention group
Group type: EXPERIMENTAL
Intervention: ERCC2 K751Q
Number of subjects: 0
Study 19470925 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCB1 3425C‐‐>T
Number of subjects: 0
Study 17845835 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation plus conventional medical management (SCS group)
Number of subjects: 100
Study 17845835 — intervention group
Group type: COMPARATOR
Intervention: Conventional medical management alone (CMM group)
Number of subjects: 100
Study 14754579 — intervention group
Group type: EXPERIMENTAL
Intervention: Succimer
Number of subjects: 780
Study 14754579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780
Study 11351919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program implemented at CVS pharmacies
Number of subjects: 1100
Study 9783644 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG reductase inhibitors
Number of subjects: 0
Study 9783644 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose reductase inhibitors
Number of subjects: 0
Study 9783644 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 7846939 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 82
Study 7846939 — intervention group
Group type: COMPARATOR
Intervention: Quinidine/Verapamil
Number of subjects: 82
Study 3048574 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulfan maintenance plus pulsed doses of cytarabine and lomustine
Number of subjects: 0
Study 3048574 — intervention group
Group type: COMPARATOR
Intervention: Busulfan maintenance
Number of subjects: 0
Study 30086252 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 110
Study 30086252 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing (povidone-iodine gauze and patch)
Number of subjects: 110
Study 27940458 — intervention group
Group type: EXPERIMENTAL
Intervention: T50 test (blood calcification propensity)
Number of subjects: 2785
Study 25373796 — intervention group
Group type: EXPERIMENTAL
Intervention: SIRT
Number of subjects: 24
Study 25373796 — intervention group
Group type: COMPARATOR
Intervention: DEB-TACE
Number of subjects: 24
Study 24242776 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic transpapillary pancreatic stenting (PTPS)
Number of subjects: 200
Study 24242776 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PTPS)
Number of subjects: 200
Study 20454974 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 MU IFN α2b s.c. 5 ×/week, followed by either 5 MU or 10 MU IFN α2b s.c. 3 ×/week for a total of 2 years
Number of subjects: 66
Study 18410952 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day)
Number of subjects: 104
Study 18410952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 17274494 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 4
Study 17274494 — intervention group
Group type: COMPARATOR
Intervention: Comparative intervention or control
Number of subjects: 4
Study 12757998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in CAST
Number of subjects: 3163
Study 12757998 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled in CAST
Number of subjects: 3163
Study 12757998 — intervention group
Group type: EXPERIMENTAL
Intervention: Under study management in CAST
Number of subjects: 3163
Study 12757998 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled in AVID
Number of subjects: 3163
Study 12757998 — intervention group
Group type: COMPARATOR
Intervention: Nonenrolled in AVID
Number of subjects: 3163
Study 10763397 — intervention group
Group type: EXPERIMENTAL
Intervention: 900-mL 75-g OGTT
Number of subjects: 10
Study 10763397 — intervention group
Group type: COMPARATOR
Intervention: 600-mL 75-g OGTT
Number of subjects: 10
Study 10763397 — intervention group
Group type: COMPARATOR
Intervention: 300-mL 75-g OGTT
Number of subjects: 10
Study 9029414 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous forskolin (75 minute infusion)
Number of subjects: 9
Study 1386905 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant vaccine
Number of subjects: 96
Study 1386905 — intervention group
Group type: COMPARATOR
Intervention: Plasma-derived vaccine
Number of subjects: 96
Study 6649055 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol plus hydrochlorothiazide plus amiloride
Number of subjects: 32
Study 6649055 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 32
Study 31515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Meat intake
Number of subjects: 32
Study 31515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugar-sweetened beverage (SSB) intake
Number of subjects: 32
Study 31515553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish intake
Number of subjects: 32
Study 31515553 — intervention group
Group type: EXPERIMENTAL
Intervention: RBCs and hair
Number of subjects: 32
Study 29880546 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive CD34+ cell therapy (group A)
Number of subjects: 60
Study 29880546 — intervention group
Group type: COMPARATOR
Intervention: Single-dose CD34+ cell therapy (group B)
Number of subjects: 60
Study 26834067 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization with microspheres alone (Bead Block [BB])
Number of subjects: 101
Study 26834067 — intervention group
Group type: COMPARATOR
Intervention: Embolization with doxorubicin-eluting microspheres (LC Bead [LCB])
Number of subjects: 101
Study 26834067 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolization with microspheres alone (BB)
Number of subjects: 101
Study 26834067 — intervention group
Group type: COMPARATOR
Intervention: Embolization with doxorubicin-eluting microspheres (LCB)
Number of subjects: 101
Study 25363186 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 (1000 mg/day)
Number of subjects: 60
Study 25363186 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 22464659 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental video module (study group)
Number of subjects: 300
Study 22464659 — intervention group
Group type: COMPARATOR
Intervention: Routine preoperative discussion (control group)
Number of subjects: 300
Study 20435865 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure at 1860 m and 2590 m (CPAP discontinued)
Number of subjects: 34
Study 20435865 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure at 2590 m (CPAP discontinued)
Number of subjects: 34
Study 20435865 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude exposure (CPAP discontinued)
Number of subjects: 34
Study 17655969 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene 0.1% - Benzoyl Peroxide 2.5% (adapalene-BPO)
Number of subjects: 517
Study 17655969 — intervention group
Group type: COMPARATOR
Intervention: Adapalene 0.1%
Number of subjects: 517
Study 17655969 — intervention group
Group type: COMPARATOR
Intervention: Benzoyl Peroxide 2.5%
Number of subjects: 517
Study 17655969 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 517
Study 15686271 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen Therapy (HBO2), 120 treatments in blocks of 80 and 40 with a five-month break
Number of subjects: 5
Study 15686271 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (normal controls)
Number of subjects: 5
Study 15686271 — intervention group
Group type: COMPARATOR
Intervention: Head injured controls (HIC)
Number of subjects: 5
Study 11431192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefepime, 1 g once daily (group A)
Number of subjects: 81
Study 11431192 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vancomycin and netilmicin at conventional doses (group B)
Number of subjects: 81
Study 9505075 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1829
Study 9505075 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1829
Study 8279402 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (15% of total energy as protein)
Number of subjects: 35
Study 8279402 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet (7.5% of energy as protein)
Number of subjects: 35
Study 2929486 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast
Number of subjects: 0
Study 2929486 — intervention group
Group type: COMPARATOR
Intervention: Omitting breakfast
Number of subjects: 0
Study 785587 — intervention group
Group type: EXPERIMENTAL
Intervention: pepstatin
Number of subjects: 9
Study 29720238 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of postoperative intravenously administered (IV) antibiotics
Number of subjects: 1066
Study 29720238 — intervention group
Group type: COMPARATOR
Intervention: 5 days of postoperative IV antibiotics
Number of subjects: 1066
Study 29720238 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 hours of postoperative IV antibiotics
Number of subjects: 1066
Study 27513155 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary Lymph Node Dissection (ALND)
Number of subjects: 891
Study 27513155 — intervention group
Group type: COMPARATOR
Intervention: Sentinel Lymph Node Dissection (SLND) alone
Number of subjects: 891
Study 27513155 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ALND and SLND)
Number of subjects: 891
Study 25029914 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock-absorbing insoles (SAIs)
Number of subjects: 75
Study 25029914 — intervention group
Group type: COMPARATOR
Intervention: Usual insoles (Control)
Number of subjects: 75
Study 23043090 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 5030
Study 23043090 — intervention group
Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 5030
Study 23043090 — intervention group
Group type: COMPARATOR
Intervention: Usual school provision
Number of subjects: 5030
Study 20383111 — intervention group
Group type: EXPERIMENTAL
Intervention: Filling with bone substitute and calcium sulphate post extraction
Number of subjects: 22
Study 20383111 — intervention group
Group type: COMPARATOR
Intervention: No filling with any type of material post extraction (control group)
Number of subjects: 22